Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q2 2025 Earnings | 08/06/2025

About this video

Rigel Pharmaceuticals, Inc. reported strong Q2 2025 financial results marked by significant growth and improved profitability. The company achieved total revenues of $101.7 million for the quarter ended June 30, 2025, including $58.9 million in net product sales—a 76% increase year-over-year—and $42.7 million in contract revenues from collaborations. Key commercial performance highlights included: Tavalisse (fostamatinib) leading with $40.1 million in sales, up 52% from Q2 2024 Gavreto (pralsetinib) contributing $11.8 million since its June 2024 launch Rezlidhia (olutasidenib) generating $7.0 million, reflecting a 36% year-over-year increase Rigel posted a net income of $59.6 million for Q2 2025, a remarkable turnaround from a net loss of $1.0 million in the same quarter last year. Basic earnings per share were $3.33, with diluted EPS of $3.28. The company strengthened its cash position to $108.4 million as of June 30, 2025, up from $77.3 million at year-end 2024. This followed a return to profitability in Q1 2025. Strategic developments include completion of enrollment in the dose escalation phase of its Phase 1b study of R289, a dual IRAK1/4 inhibitor for relapsed or refractory lower-risk myelodysplastic syndrome (MDS). Rigel anticipates sharing updated data later in 2025 and plans to begin dose expansion in the second half of the year. The company also advanced its olutasidenib program into glioma with plans for a Phase 2 study. Collaborations with institutions like MD Anderson Cancer Center continue to progress. Based on strong first-half performance, Rigel raised its full-year 2025 guidance, now targeting total revenues of approximately $270 to $280 million and net product sales of $210 to $220 million, significantly above previous forecasts. The company expects to remain profitable while funding its development pipeline. Rigel’s focus on commercial execution, pipeline expansion, and financial discipline positions it well for sustained growth in hematology and oncology. About Inside Ticker: For more expert analysis and real-time updates on Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #RigelPharmaceuticals #RIGL #Q22025 #Earnings #FinancialResults #NetIncome #Revenue #NetProductSales #Tavalisse #Gavreto #Rezlidhia #Hematology #Oncology #IRAKInhibitor #R289 #ClinicalTrials #Pipeline #Collaboration #MDAnderson #Biotech #NASDAQ #InsideTicker #2025Outlook #InvestorUpdate